Company: INMB
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001213900-25-104141
Chunk: 39

Company: Inmune Bio, Inc.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 1
Chunk 39
---
5  
    2024  
    2025  
    2024 
  
    External Costs 

    DN-TNF - Alzheimer’s disease 
    $1,188  
    $7,629  
    $9,289  
    $18,759 
  
    INKmune - High Risk MDS/AML & Prostate cancer and CORDStrom 
     1,084  
     1,214  
     3,449  
     3,468 
  
    Preclinical and other programs 
     90  
     157  
     152  
     518 
  
    Accrued research and development rebate 
     (150) 
     (262) 
     (486) 
     (1,524)
  
    Total external costs 
     2,212  
     8,738  
     12,404  
     21,221 
  
    Internal costs 
     2,675  
     1,329  
     5,926  
     4,592 
  
    Total 
    $4,887  
    $10,067  
    $18,330  
    $25,813 

We typically use our employee
resources across our development programs. We track outsourced development costs by product candidate or development program, but we do
not allocate internal costs personnel costs including salaries and stock-based compensation to specific product candidates or development
programs.

We
participate, through our wholly owned subsidiary in Australia, in the Australian research and development tax incentive program, such
that a percentage of our qualifying research and development expenditures are reimbursed by the Australian government, and such incentives
are reflected as a reduction of research and development expense. The Australian research and development tax incentive is recognized
when there is reasonable assurance that the incentive will be received, the relevant expenditure has been incurred and the amount of the
consideration can be reliably measured. 

We
participate, through our wholly owned subsidiary in the United Kingdom, in the research and development program provided by the United
Kingdom tax relief program, such that a percentage of our qualifying research and development expenditures are reimbursed by the United
Kingdom government, and such incentives are reflected as a reduction of research and development expense. The United Kingdom research
and development tax incentive is recognized when there is reasonable assurance that the incentive will be